Myopia (short-sightedness) is an optical inconvenience, requiring glasses or contact lenses or laser eye surgery. It imposes major challenges and costs for refractive correction, and for the treatment of associated pathological complications. Myopia is the leading cause of blindness in parts of East-Asia, and a top 3 cause in Ireland and parts of Europe, and is the leading cause of blindness among working age people in Europe.
Treatment of Myopia
Currently accepted myopia treatments address only the visual blur caused by myopia. Treatment options for myopia related blindness, however, are limited. Treatment options such as under-correction of myopia, gas permeable contact lenses, and bifocal or multifocal spectacles have all been proven to be ineffective for myopia control, and no optical or pharmacological intervention has been adopted into routine clinical practice. The current state of the art, however, suggests two viable control candidates, atropine and peripheral-plus contact lenses.
CERI team is working to find a means to control and prevent myopia (short-sightedness) in children.
Our research is broad ranging, it includes:
- Schools projects to engage children, teachers and parents and inform them of the risks of myopia
- Clinical trials to investigate the potential of eye drops and contact lenses to slow down the progression of myopia
- Novel technology development projects to determine peoples risk of developing myopia, and biomedical devices for the prevention and optimal control of myopia.
We are now recruiting children to MOSAIC and CHAMP clinical trials, the first trials in a European population to assess the capacity of low-dose atropine eye drops to halt myopia. Given the inconvenience to people, the costs associated with lifelong care and the untreatable blindness it causes, this research could lead to dramatic and important public health benefit to communities and families in Ireland and across the world.
1. Holden B, Fricke T et al. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. Ophthalmology 2016; Volume 123, Issue 5, Pages 1036–1042
MOSAIC (Myopia Outcome Study of Atropine In Children)
CHAMP (Children using Atropine for reduction of Myopia Progression)